U.S. Court in Massachusetts Allows Government to Shift FCA Liability Theories in Kickback-Related Action Against Regeneron
- August 15, 2025
The federal government can shift to a “false certification” theory of liability under the False Claims Act (FCA) in its action alleging Regeneron Pharmaceuticals, Inc. improperly funneled millions of dollars to a Chronic Disease Fund (CDF) to subsidize patient copays for its drug Eylea, the U.S. District Court for the District of Massachusetts said August 4.
ARTICLE TAGS
You must be logged in to access this content.